ArticleBMJ open ophthalmology2025
Forecasting trends in glaucoma medication reimbursees in Finland: updated system dynamics model to 2070.
Article in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsGlaucoma is among the leading causes of permanent visual impairment, with its prevalence increasing due to population ageing. This study aimed to evaluate the accuracy of the 2004 system dynamics (SD) model predicting the number of glaucoma medication reimbursees in Finland until 2023, update the model using 1990-2023 data to forecast medication users until 2070 and assess whether the observed deceleration in net growth during 2015-2023 represented a temporary or sustained trend.
methodsData on reimbursed glaucoma medication users (1986-2023) were sourced from the Finnish Social Insurance Institution, alongside Finnish population projections (2021-2070). An updated SD model was developed using historical data, stratified by age groups, and incorporating demographic shifts, mortality and migration. Predictions were validated against observed trends and parameterised using expert consensus and literature estimates.
resultsBy 2070 in Finland, the updated model predicts a 57% increase in glaucoma medication reimbursees (151 846 individuals; 28 per 1000 inhabitants), primarily driven by growth in ≥75-year-old population. The updated model captured the slowdown in net growth of reimbursees in 2015-2023. A similar slowdown is projected to reoccur during 2033-2048, again followed by an acceleration in growth.
conclusionsThe demand for glaucoma care in Finland will increase by 2070, necessitating proactive resource allocation and continuous monitoring using real-world data to ensure optimal care delivery. Temporary changes in the demand for glaucoma care underscore the need for adaptive forecasting methods. The updated model provides a framework for monitoring trends and informing resource allocation in national eye care systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.